The DOI matches its Crossref record; 280 of the 280 references it cites were found in a registry or an index.
Control of human toxoplasmosis
Open accessAbstract
Toxoplasmosis is caused by Toxoplasma gondii, an apicomplexan parasite that is able to infect any nucleated cell in any warm-blooded animal. Toxoplasma gondii infects around 2 billion people and, whilst only a small percentage of infected people will suffer serious disease, the prevalence of the parasite makes it one of the most damaging zoonotic diseases in the world. Toxoplasmosis is a disease with multiple manifestations: it can cause a fatal encephalitis in immunosuppressed people; if first contracted during pregnancy, it can cause miscarriage or congenital defects in the neonate; and it can cause serious ocular disease, even in immunocompetent people. The disease has a complex epidemiology, being transmitted by ingestion of oocysts that are shed in the faeces of definitive feline hosts and contaminate water, soil and crops, or by consumption of intracellular cysts in undercooked meat from intermediate hosts. In this review we examine current and future approaches to control toxoplasmosis, which encompass a variety of measures that target different components of the life cycle of T. gondii. These include: education programs about the parasite and avoidance of contact with infectious stages; biosecurity and sanitation to ensure food and water safety; chemo- and immunotherapeutics to control active infections and disease; prophylactic options to prevent acquisition of infection by livestock and cyst formation in meat; and vaccines to prevent shedding of oocysts by definitive feline hosts.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toxoplasma gondii: from animals to humans
Tenter, A. M., Heckeroth, A. R., & Weiss, L. M. (2000) · International Journal for Parasitology · doi:10.1016/s0020-7519(00)00124-7 · Cited by 3,702
Montoya, J., & Liesenfeld, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16412-x · Cited by 3,232
Trained immunity: A program of innate immune memory in health and– disease
Netea, M. G., Joosten, L. A. B., Latz, E., Mills, K. H. G., Natoli, G., Stunnenberg, H. G., O’Neill, L. A. J., & Xavier, R. J. (2016) · Science · doi:10.1126/science.aaf1098 · Cited by 2,768
Defining trained immunity and its role in health and disease
Netea, M. G., Domínguez-Andrés, J., Barreiro, L. B., Chavakis, T., Divangahi, M., Fuchs, E., Joosten, L. A. B., van der Meer, J. W. M., Mhlanga, M. M., Mulder, W. J. M., et al. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0285-6 · Cited by 2,690
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
Toxoplasmic Encephalitis in AIDS
Luft, B. J., & Remington, J. S. (1992) · Clinical Infectious Diseases · doi:10.1093/clinids/15.2.211 · Cited by 1,287
BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosis
Kaufmann, E., Sanz, J., Dunn, J. L., Khan, N., Mendonça, L. E., Pacis, A., Tzelepis, F., Pernet, E., Dumaine, A., Grenier, J.-C., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.031 · Cited by 1,191
Arts, R. J. W., Moorlag, S. J. C. F. M., Novakovic, B., Li, Y., Wang, S.-Y., Oosting, M., Kumar, V., Xavier, R. J., Wijmenga, C., Joosten, L. A. B., et al. (2018) · Cell Host & Microbe · doi:10.1016/j.chom.2017.12.010 · Cited by 1,179
Interferon-γ: the Major Mediator of Resistance Against Toxoplasma gondii
Suzuki, Y., Orellana, M. A., Schreiber, R. D., & Remington, J. S. (1988) · Science · doi:10.1126/science.3128869 · Cited by 1,173
Inhibitors of the Nonmevalonate Pathway of Isoprenoid Biosynthesis as Antimalarial Drugs
Jomaa, H., Wiesner, J., Sanderbrand, S., Altincicek, B., Weidemeyer, C., Hintz, M., Türbachova, I., Eberl, M., Zeidler, J., Lichtenthaler, H. K., et al. (1999) · Science · doi:10.1126/science.285.5433.1573 · Cited by 1,173
Pappas, G., Roussos, N., & Falagas, M. E. (2009) · International Journal for Parasitology · doi:10.1016/j.ijpara.2009.04.003 · Cited by 1,161
Biogenic synthesis of nanoparticles: A review
Sharma, D., Kanchi, S., & Bisetty, K. (2019) · Arabian Journal of Chemistry · doi:10.1016/j.arabjc.2015.11.002 · Cited by 948
Toxoplasmosis: A history of clinical observations
Weiss, L. M., & Dubey, J. P. (2009) · International Journal for Parasitology · doi:10.1016/j.ijpara.2009.02.004 · Cited by 885
Selective Stimulation of T Cell Subsets with Antibody-Cytokine Immune Complexes
Boyman, O., Kovar, M., Rubinstein, M. P., Surh, C. D., & Sprent, J. (2006) · Science · doi:10.1126/science.1122927 · Cited by 870
Host-directed therapies for bacterial and viral infections
Kaufmann, S. H. E., Dorhoi, A., Hotchkiss, R. S., & Bartenschlager, R. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.162 · Cited by 831
Nanomedicine: Principles, Properties, and Regulatory Issues
Soares, S., Sousa, J., Pais, A., & Vitorino, C. (2018) · Frontiers in Chemistry · doi:10.3389/fchem.2018.00360 · Cited by 790
The global burden of congenital toxoplasmosis: a systematic review
Torgerson, P. R., & Mastroiacovo, P. (2013) · Bulletin of the World Health Organization · doi:10.2471/blt.12.111732 · Cited by 748
Nuclear-encoded proteins target to the plastid in Toxoplasma gondii and Plasmodium falciparum
Waller, R. F., Keeling, P. J., Donald, R. G. K., Striepen, B., Handman, E., Lang-Unnasch, N., Cowman, A. F., Besra, G. S., Roos, D. S., & McFadden, G. I. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.21.12352 · Cited by 714
Outbreak of toxoplasmosis associated with municipal drinking water
Bowie, W. R., King, A. S., Werker, D. H., Isaac-Renton, J. L., Bell, A., Eng, S. B., & Marion, S. A. (1997) · The Lancet · doi:10.1016/s0140-6736(96)11105-3 · Cited by 704
Clinical Practice: Management of Toxoplasma gondii Infection during Pregnancy
Montoya, J. G., & Remington, J. S. (2008) · Clinical Infectious Diseases · doi:10.1086/590149 · Cited by 690
Cancer immunotherapy—immune checkpoint blockade and associated endocrinopathies.
Byun, D. J., Wolchok, J. D., Rosenberg, L. M., & Girotra, M. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2016.205 · Cited by 685 · cited 1×
“With the more recent and widespread use of monoclonal antibody (mAb) therapy in the treatment of cancer (Byun et al., 2017), passive immunisation with mAbs in toxoplasmosis has been revitalised.”
BackgroundOldenhove, G., Bouladoux, N., Wohlfert, E. A., Hall, J. A., Chou, D., Dos santos, L., O'Brien, S., Blank, R., Lamb, E., Natarajan, S., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.10.001 · Cited by 575
Treatment of Toxoplasmosis: Historical Perspective, Animal Models, and Current Clinical Practice
Dunay, I. R., Gajurel, K., Dhakal, R., Liesenfeld, O., & Montoya, J. G. (2018) · Clinical Microbiology Reviews · doi:10.1128/cmr.00057-17 · Cited by 553
Fry, M., & Pudney, M. (1992) · Biochemical Pharmacology · doi:10.1016/0006-2952(92)90213-3 · Cited by 529
Highly Endemic, Waterborne Toxoplasmosis in North Rio de Janeiro State, Brazil
Bahia-Oliveira, L. M. G., Jones, J. L., Azevedo-Silva, J., Alves, C. C. F., Oréfice, F., & Addiss, D. G. (2003) · Emerging Infectious Diseases · doi:10.3201/eid0901.020160 · Cited by 518
Targeting the CCL2-CCR2 signaling axis in cancer metastasis
Lim, S. Y., Yuzhalin, A. E., Gordon-Weeks, A. N., & Muschel, R. J. (2016) · Oncotarget · doi:10.18632/oncotarget.7376 · Cited by 501
Innate immunity to Toxoplasma gondii infection
Yarovinsky, F. (2014) · Nature Reviews Immunology · doi:10.1038/nri3598 · Cited by 462
Duration of Immunity to Shedding of Toxoplasma gondii Oocysts by Cats
Dubey, J. P. (1995) · The Journal of Parasitology · doi:10.2307/3283823 · Cited by 444
Toxoplasma gondii infection and toxoplasmosis in farm animals: Risk factors and economic impact
Stelzer, S., Basso, W., Benavides Silván, J., Ortega-Mora, L. M., Maksimov, P., Gethmann, J., Conraths, F. J., & Schares, G. (2019) · Food and Waterborne Parasitology · doi:10.1016/j.fawpar.2019.e00037 · Cited by 441
Gr1+ Inflammatory Monocytes Are Required for Mucosal Resistance to the Pathogen Toxoplasma gondii
Dunay, I. R., DaMatta, R. A., Fux, B., Presti, R., Greco, S., Colonna, M., & Sibley, L. D. (2008) · Immunity · doi:10.1016/j.immuni.2008.05.019 · Cited by 432
Environmental transmission of Toxoplasma gondii: Oocysts in water, soil and food
Shapiro, K., Bahia-Oliveira, L., Dixon, B., Dumètre, A., de Wit, L. A., VanWormer, E., & Villena, I. (2019) · Food and Waterborne Parasitology · doi:10.1016/j.fawpar.2019.e00049 · Cited by 422
Chahal, J. S., Khan, O. F., Cooper, C. L., McPartlan, J. S., Tsosie, J. K., Tilley, L. D., Sidik, S. M., Lourido, S., Langer, R., Bavari, S., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1600299113 · Cited by 414
The socioeconomic burden of parasitic zoonoses: Global trends
Torgerson, P. R., & Macpherson, C. N. L. (2011) · Veterinary Parasitology · doi:10.1016/j.vetpar.2011.07.017 · Cited by 404
Toxoplasma gondii and Other Risk Factors for Schizophrenia: An Update
Torrey, E. F., Bartko, J. J., & Yolken, R. H. (2012) · Schizophrenia Bulletin · doi:10.1093/schbul/sbs043 · Cited by 403
Control of the risk of human toxoplasmosis transmitted by meat
Kijlstra, A., & Jongert, E. (2008) · International Journal for Parasitology · doi:10.1016/j.ijpara.2008.06.002 · Cited by 371
Toxoplasma gondii Infection in the United States, 1999–2004, Decline from the Prior Decade
Jones, J. L., Kruszon-Moran, D., Sanders-Lewis, K., & Wilson, M. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.405 · Cited by 370
Combined IL-15/IL-15Rα Immunotherapy Maximizes IL-15 Activity In Vivo
Stoklasek, T. A., Schluns, K. S., & Lefrançois, L. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.9.6072 · Cited by 366
Prevention of toxoplasmosis in transplant patients
Derouin, F., & Pelloux, H. (2008) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2008.02091.x · Cited by 365
Dannemann, B., McCutchan, J. A., Israelski, D., Antoniskis, D., Leport, C., Luft, B., Nussbaum, J., Clumeck, N., Morlat, P., Chiu, J., et al. (1992) · Annals of Internal Medicine · doi:10.7326/0003-4819-116-1-33 · Cited by 360
(2014) · doi:10.1016/c2011-0-07157-0 · Cited by 352
Waterborne Toxoplasmosis, Brazil, from Field to Gene
de Moura, L., Bahia-Oliveira, L. M. G., Wada, M. Y., Jones, J. L., Tuboi, S. H., Carmo, E. H., Ramalho, W. M., Camargo, N. J., Trevisan, R., Graça, R. M. T., et al. (2006) · Emerging Infectious Diseases · doi:10.3201/eid1202.041115 · Cited by 345
Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in Toxoplasma
Lourido, S., Shuman, J., Zhang, C., Shokat, K. M., Hui, R., & Sibley, L. D. (2010) · Nature · doi:10.1038/nature09022 · Cited by 342
Drugs in development for toxoplasmosis: advances, challenges, and current status
Alday, H., & Doggett, J. (2017) · Drug Design, Development and Therapy · doi:10.2147/dddt.s60973 · Cited by 321
A commercial vaccine for ovine toxoplasmosis
Buxton, D., & Innes, E. A. (1995) · Parasitology · doi:10.1017/s003118200000144x · Cited by 317
Calcium-Dependent Signaling and Kinases in Apicomplexan Parasites
Billker, O., Lourido, S., & Sibley, L. D. (2009) · Cell Host & Microbe · doi:10.1016/j.chom.2009.05.017 · Cited by 314
Toxoplasma gondii Infection in Immunocompromised Patients: A Systematic Review and Meta-Analysis
Wang, Z.-D., Liu, H.-H., Ma, Z.-X., Ma, H.-Y., Li, Z.-Y., Yang, Z.-B., Zhu, X.-Q., Xu, B., Wei, F., & Liu, Q. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00389 · Cited by 311
Congenital Toxoplasmosis: A Review
Jones, J. L., Lopez, A., Wilson, M., Schulkin, J., & Gibbs, R. (2001) · Obstetric and Gynecologic Survey · doi:10.1097/00006254-200105000-00025 · Cited by 305
Braun, L., Brenier-Pinchart, M.-P., Yogavel, M., Curt-Varesano, A., Curt-Bertini, R.-L., Hussain, T., Kieffer-Jaquinod, S., Coute, Y., Pelloux, H., Tardieux, I., et al. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20130103 · Cited by 272
Vaccine impact: Benefits for human health
Doherty, M., Buchy, P., Standaert, B., Giaquinto, C., & Prado- Cohrs, D. (2016) · Vaccine · doi:10.1016/j.vaccine.2016.10.025 · Cited by 272
Oocyst-Transmitted Toxoplasmosis Associated with Ingestion of Contaminated Water
Benenson, M. W., Takafuji, E. T., Lemon, S. M., Greenup, R. L., & Sulzer, A. J. (1982) · New England Journal of Medicine · doi:10.1056/nejm198209093071107 · Cited by 271
Lorenzi, H., Khan, A., Behnke, M. S., Namasivayam, S., Swapna, L. S., Hadjithomas, M., Karamycheva, S., Pinney, D., Brunk, B. P., Ajioka, J. W., et al. (2016) · Nature Communications · doi:10.1038/ncomms10147 · Cited by 271
A Selective Review of Advances in Coccidiosis Research
Chapman, H. D., Barta, J. R., Blake, D., Gruber, A., Jenkins, M., Smith, N. C., Suo, X., & Tomley, F. M. (2013) · Advances in Parasitology · doi:10.1016/b978-0-12-407705-8.00002-1 · Cited by 268
Self-citationIdentification of a Master Regulator of Differentiation in Toxoplasma
Waldman, B. S., Schwarz, D., Wadsworth, M. H., Saeij, J. P., Shalek, A. K., & Lourido, S. (2020) · Cell · doi:10.1016/j.cell.2019.12.013 · Cited by 263
Real-Time PCR for Quantitative Detection of Toxoplasma gondii
Lin, M.-H., Chen, T.-C., Kuo, T.-T., Tseng, C.-C., & Tseng, C.-P. (2000) · Journal of Clinical Microbiology · doi:10.1128/jcm.38.11.4121-4125.2000 · Cited by 260
Mazumdar, J., H. Wilson, E., Masek, K., A. Hunter, C., & Striepen, B. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0603391103 · Cited by 253
Kang, H., Remington, J. S., & Suzuki, Y. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.5.2629 · Cited by 250
Spillman, N. J., Allen, R. J. W., McNamara, C. W., Yeung, B. K. S., Winzeler, E. A., Diagana, T. T., & Kirk, K. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2012.12.006 · Cited by 246
Genome editing with the CRISPR‐Cas system: an art, ethics and global regulatory perspective
Zhang, D., Hussain, A., Manghwar, H., Xie, K., Xie, S., Zhao, S., Larkin, R. M., Qing, P., Jin, S., & Ding, F. (2020) · Plant Biotechnology Journal · doi:10.1111/pbi.13383 · Cited by 233
Molecular mimicry of a CCR5 binding-domain in the microbial activation of dendritic cells
Aliberti, J., Valenzuela, J. G., Carruthers, V. B., Hieny, S., Andersen, J., Charest, H., e Sousa, C. R., Fairlamb, A., Ribeiro, J. M., & Sher, A. (2003) · Nature Immunology · doi:10.1038/ni915 · Cited by 230
CAR T cells for infection, autoimmunity and allotransplantation
Maldini, C. R., Ellis, G. I., & Riley, J. L. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0042-2 · Cited by 229
Trans-presentation: A novel mechanism regulating IL-15 delivery and responses
Stonier, S. W., & Schluns, K. S. (2010) · Immunology Letters · doi:10.1016/j.imlet.2009.09.009 · Cited by 226
Gastrointestinal inflammation and associated immune activation in schizophrenia
Severance, E. G., Alaedini, A., Yang, S., Halling, M., Gressitt, K. L., Stallings, C. R., Origoni, A. E., Vaughan, C., Khushalani, S., Leweke, F. M., et al. (2012) · Schizophrenia Research · doi:10.1016/j.schres.2012.02.025 · Cited by 226
Wilking, H., Thamm, M., Stark, K., Aebischer, T., & Seeber, F. (2016) · Scientific Reports · doi:10.1038/srep22551 · Cited by 224
Watts, E., Zhao, Y., Dhara, A., Eller, B., Patwardhan, A., & Sinai, A. P. (2015) · mBio · doi:10.1128/mbio.01155-15 · Cited by 223
Toxoplasma oocysts as a public health problem
Torrey, E. F., & Yolken, R. H. (2013) · Trends in Parasitology · doi:10.1016/j.pt.2013.06.001 · Cited by 222
Araujo, F. G., Huskinson, J., & Remington, J. S. (1991) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.35.2.293 · Cited by 220
B Cells Are Essential for Vaccination-Induced Resistance to Virulent Toxoplasma gondii
Sayles, P. C., Gibson, G. W., & Johnson, L. L. (2000) · Infection and Immunity · doi:10.1128/iai.68.3.1026-1033.2000 · Cited by 218
Ambade, A., Lowe, P., Kodys, K., Catalano, D., Gyongyosi, B., Cho, Y., Iracheta‐Vellve, A., Adejumo, A., Saha, B., Calenda, C., et al. (2019) · Hepatology · doi:10.1002/hep.30249 · Cited by 214
Toxoplasma gondii: Isolation and preliminary characterization of temperature-sensitive mutants
Pfefferkorn, E. R., & Pfefferkorn, L. G. (1976) · Experimental Parasitology · doi:10.1016/0014-4894(76)90040-0 · Cited by 203
Saksouk, N., Bhatti, M. M., Kieffer, S., Smith, A. T., Musset, K., Garin, J., Sullivan, W. J., Cesbron-Delauw, M.-F., & Hakimi, M.-A. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.23.10301-10314.2005 · Cited by 200
In vitro assays elucidate peculiar kinetics of clindamycin action against Toxoplasma gondii
Fichera, M. E., Bhopale, M. K., & Roos, D. S. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1530 · Cited by 195
Several HLA alleles share overlapping peptide specificities.
Sidney, J., del Guercio, M. F., Southwood, S., Engelhard, V. H., Appella, E., Rammensee, H. G., Falk, K., Rötzschke, O., Takiguchi, M., Kubo, R. T., et al. (1995) · The Journal of Immunology · doi:10.4049/jimmunol.154.1.247 · Cited by 194
Tomita, T., Bzik, D. J., Ma, Y. F., Fox, B. A., Markillie, L. M., Taylor, R. C., Kim, K., & Weiss, L. M. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003823 · Cited by 193
Drug inhibition of HDAC3 and epigenetic control of differentiation in Apicomplexa parasites
Bougdour, A., Maubon, D., Baldacci, P., Ortet, P., Bastien, O., Bouillon, A., Barale, J.-C., Pelloux, H., Ménard, R., & Hakimi, M.-A. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082826 · Cited by 191
Toxoplasma gondii calcium-dependent protein kinase 1 is a target for selective kinase inhibitors
Ojo, K. K., Larson, E. T., Keyloun, K. R., Castaneda, L. J., DeRocher, A. E., Inampudi, K. K., Kim, J. E., Arakaki, T. L., Murphy, R. C., Zhang, L., et al. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1818 · Cited by 191
Ramakrishnan, C., Maier, S., Walker, R. A., Rehrauer, H., Joekel, D. E., Winiger, R. R., Basso, W. U., Grigg, M. E., Hehl, A. B., Deplazes, P., et al. (2019) · Scientific Reports · doi:10.1038/s41598-018-37671-8 · Cited by 188
Self-citationEndochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis
Doggett, J. S., Nilsen, A., Forquer, I., Wegmann, K. W., Jones-Brando, L., Yolken, R. H., Bordón, C., Charman, S. A., Katneni, K., Schultz, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208069109 · Cited by 187
Wang, J.-L., Zhang, N.-Z., Li, T.-T., He, J.-J., Elsheikha, H. M., & Zhu, X.-Q. (2019) · Trends in Parasitology · doi:10.1016/j.pt.2019.01.005 · Cited by 187
McLeod, R., Muench, S. P., Rafferty, J. B., Kyle, D. E., Mui, E. J., Kirisits, M. J., Mack, D. G., Roberts, C. W., Samuel, B. U., Lyons, R. E., et al. (2001) · International Journal for Parasitology · doi:10.1016/s0020-7519(01)00111-4 · Cited by 185
CCR5 Is Essential for NK Cell Trafficking and Host Survival following Toxoplasma gondii Infection
Khan, I. A., Thomas, S. Y., Moretto, M. M., Lee, F. S., Islam, S. A., Combe, C., Schwartzman, J. D., & Luster, A. D. (2006) · PLoS Pathogens · doi:10.1371/journal.ppat.0020049 · Cited by 182
Host cells: mobilizable lipid resources for the intracellular parasite Toxoplasma gondii
Charron, A. J., & Sibley, L. D. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.15.3049 · Cited by 180
Adverse Event Profile of Pyrimethamine-Based Therapy in Toxoplasmosis: A Systematic Review
Ben-Harari, R. R., Goodwin, E., & Casoy, J. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0206-8 · Cited by 180
dos Santos, J. C., de Figueiredo, A. M. B., Silva, M. V. T., Cirovic, B., de Bree, L. C. J., Damen, M. S. M. A., Moorlag, S. J. C. F. M., Gomes, R. S., Helsen, M. M. A., Oosting, M., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.08.004 · Cited by 180
A plastid segregation defect in the protozoan parasite Toxoplasma gondii
He, C. Y. (2001) · The EMBO Journal · doi:10.1093/emboj/20.3.330 · Cited by 178
Metabolic Pathways in the Apicoplast of Apicomplexa
Seeber, F., & Soldati‐Favre, D. (2010) · International review of cytology · doi:10.1016/s1937-6448(10)81005-6 · Cited by 170
McFadden, D. C., Tomavo, S., Berry, E. A., & Boothroyd, J. C. (2000) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(00)00184-5 · Cited by 170
Toxoplasmosis: the first commercial vaccine
Buxton, D. (1993) · Parasitology Today · doi:10.1016/0169-4758(93)90236-9 · Cited by 169
Jones, J. L., Kruszon‐Moran, D., Rivera, H. N., Price, C. E., & Wilkins, P. P. (2014) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.14-0013 · Cited by 167
Bhadra, R., Gigley, J. P., Weiss, L. M., & Khan, I. A. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1015298108 · Cited by 163
Human impact on the diversity and virulence of the ubiquitous zoonotic parasite Toxoplasma gondii
Shwab, E. K., Saraf, P., Zhu, X., Zhou, D., McFerrin, B. M., Ajzenberg, D., Schares, G., Hammond-Aryee, K., van Helden, P. D., Higgins, S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1722202115 · Cited by 157
Nair, S. C., Brooks, C. F., Goodman, C. D., Strurm, A., McFadden, G. I., Sundriyal, S., Anglin, J. L., Song, Y., Moreno, S. N. J., & Striepen, B. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20110039 · Cited by 156
Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer
Aldinucci, D., & Casagrande, N. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19051477 · Cited by 150
Di-n-ブチルフタレートは,マウス卵巣胞状濾胞における細胞周期およびアポトーシス経路に関与する遺伝子の発現を混乱させる
Zelieann, R. C., Patrick, R. H., Wang, W., Ziv‐Gal, A., & Jodi, A. F. (2013) · Biology of Reproduction · Cited by 147
Review on the Current Trends of Toxoplasmosis Serodiagnosis in Humans
Ybañez, R. H. D., Ybañez, A. P., & Nishikawa, Y. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.00204 · Cited by 144
Bissati, K. E., Levigne, P., Lykins, J. D., V, Adlaoui, E. B., Barkat, A., Berraho, A., Laboudi, M., Mansouri, B. E., Ibrahimi, A., Rhajaoui, M., et al. (2018) · Emerging Microbes & Infections · doi:10.1038/s41426-018-0164-4 · Cited by 140
Diversity of Toxoplasma gondii strains at the global level and its determinants
Galal, L., Hamidović, A., Dardé, M., & Mercier, A. (2019) · Food and Waterborne Parasitology · doi:10.1016/j.fawpar.2019.e00052 · Cited by 137
Complex Immune Cell Interplay in the Gamma Interferon Response during Toxoplasma gondii Infection
Sturge, C. R., & Yarovinsky, F. (2014) · Infection and Immunity · doi:10.1128/iai.01722-14 · Cited by 134
Detection and prevalence of protozoan parasites in ready-to-eat packaged salads on sale in Italy
Caradonna, T., Marangi, M., CHIERICO, F. D., Ferrari, N., Reddel, S., Bracaglia, G., Normanno, G., Putignani, L., & Giangaspero, A. (2017) · Food Microbiology · doi:10.1016/j.fm.2017.06.006 · Cited by 133
Farhat, D. C., Swale, C., Dard, C., Cannella, D., Ortet, P., Barakat, M., Sindikubwabo, F., Belmudes, L., Bock, P. D., Couté, Y., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0674-4 · Cited by 133
Toxoplasmosis‐Related Knowledge and Practices AmongPregnant Women in the United States
Jones, J. L., Ogunmodede, F., Scheftel, J. M., Kirkland, E. G., Lopez, A. S., Schulkin, J. A., & Lynfield, R. (2003) · Infectious Diseases in Obstetrics and Gynecology · doi:10.1080/10647440300025512 · Cited by 131
Toxoplasma Modulates Signature Pathways of Human Epilepsy, Neurodegeneration & Cancer
Ngô, H. M., Zhou, Y., Lorenzi, H., Wang, K., Kim, T., Zhou, Y. F., Bissati, K. E., Mui, E. J., Fraczek, L., Rajagopala, S. V., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-10675-6 · Cited by 130
Mateus‐Pinilla, N. E., Dubey, J. P., Choromanski, L. J., & Weigel, R. M. (1999) · Journal of Parasitology · doi:10.2307/3285821 · Cited by 128
Intervention Strategies to Reduce Human Toxoplasma gondii Disease Burden
Opsteegh, M., Kortbeek, T. M., Havelaar, A. H., & van der Giessen, J. W. B. (2015) · Clinical Infectious Diseases · doi:10.1093/cid/ciu721 · Cited by 127
Therapeutic antibodies for infectious diseases
Sparrow, E. G., Friede, M., Sheikh, M., & Torvaldsen, S. (2017) · Bulletin of the World Health Organization · doi:10.2471/blt.16.178061 · Cited by 127
Application of IL-2 therapy to target T regulatory cell function
Shevach, E. M. (2012) · Trends in Immunology · doi:10.1016/j.it.2012.07.007 · Cited by 126
Sharma, S., Hofflin, J. M., & Remington, J. S. (1985) · The Journal of Immunology · doi:10.4049/jimmunol.135.6.4160 · Cited by 125
IL-15 augments CD8+ T cell-mediated immunity against Toxoplasma gondii infection in mice
Khan, I. A., & Kasper, L. H. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.5.2103 · Cited by 125
Frédéric Thomas, A., Lafferty, K. D., Jacques Brodeur, B., Elguero, É., Gauthier‐Clerc, M., & Missé, D. (2011) · Biology Letters · doi:10.1098/rsbl.2011.0588 · Cited by 123
Prospective vaccine prepared from a new mutant of Toxoplasma gondii for use in cats
Frenkel, J. K., Pfefferkorn, E. R., Smith, D. D., & Fishback, J. L. (1991) · American Journal of Veterinary Research · doi:10.2460/ajvr.1991.52.05.759 · Cited by 122
Hehl, A. B., Basso, W., Lippuner, C., Ramakrishnan, C., Okoniewski, M. J., Walker, R. A., Grigg, M. E., Smith, N. C., & Deplazes, P. (2015) · BMC Genomics · doi:10.1186/s12864-015-1225-x · Cited by 121
Self-citationTheToxoplasma gondii-Shuttling Function of Dendritic Cells Is Linked to the Parasite Genotype
Lambert, H., Vutova, P. P., Adams, W. C. T., Loré, K., & Barragán, A. (2009) · Infection and Immunity · doi:10.1128/iai.01289-08 · Cited by 120
Development of CRISPR/Cas9 for Efficient Genome Editing in Toxoplasma gondii
Shen, B., Brown, K. M., Long, S., & Sibley, L. D. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-6472-7_6 · Cited by 118
Chitosan and silver nanoparticles: Promising anti-toxoplasma agents
Gaafar, M. R., Mady, R. F., Diab, R. G., & Shalaby, T. I. A. (2014) · Experimental Parasitology · doi:10.1016/j.exppara.2014.05.005 · Cited by 116
Interleukin-18 (IL-18) Enhances Innate IL-12-Mediated Resistance to Toxoplasma gondii
Cai, G., Kastelein, R., & Hunter, C. A. (2000) · Infection and Immunity · doi:10.1128/iai.68.12.6932-6938.2000 · Cited by 116
Manipulating the chemokine‐chemokine receptor network to treat cancer
Ruffini, P. A., Morandi, P., Cabıoğlu, N., Altundağ, K., & Cristofanilli, M. (2007) · Cancer · doi:10.1002/cncr.22706 · Cited by 114
Casciotti, L., Ely, K. H., Williams, M. E., & Khan, I. A. (2002) · Infection and Immunity · doi:10.1128/iai.70.2.434-443.2002 · Cited by 114
Hunter, C. A., Neyer, L., Gabriel, K. E., Kennedy, M., Grabstein, K. H., Linsley, P. S., & Remington, J. S. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.158.5.2285 · Cited by 111
Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases
Shapira, Y., Agmon‐Levin, N., Selmi, C. F., Petríková, J., Barzilai, O., Ram, M., Bizzaro, N., Valentini, G., Matucci‐Cerinic, M., Anaya, J., et al. (2012) · Journal of Autoimmunity · doi:10.1016/j.jaut.2012.01.001 · Cited by 111
Isoprenoid Metabolism in Apicomplexan Parasites
Imlay, L. S., & John, A. R. O. (2014) · Current Clinical Microbiology Reports · doi:10.1007/s40588-014-0006-7 · Cited by 111
A one health approach to vaccines against Toxoplasma gondii
Innes, E. A., Hamilton, C. M., Garcia, J. L., Chryssafidis, A. L., & Smith, D. W. (2019) · Food and Waterborne Parasitology · doi:10.1016/j.fawpar.2019.e00053 · Cited by 111
Studies on the role of interleukin-12 in acute murine toxoplasmosis.
Hunter, C. A., Candolfi, E., Subauste, C. S., Cleave, V. H. V., & Remington, J. S. (1995) · PubMed Central · Cited by 106
Veterinary vaccines against Toxoplasma gondii
Innes, E. A., Bartley, P. M., Maley, S. W., Katzer, F., & Buxton, D. (2009) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762009000200018 · Cited by 105
Prenatal education for congenital toxoplasmosis
Mario, S. D., Basevi, V., Gagliotti, C., Spettoli, D., Gori, G., D’Amico, R., & Magrini, N. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006171.pub4 · Cited by 102
Tarancón, R., Domínguez‐Andrés, J., Uranga, S., Ferreira, A. V., Groh, L. A., Domenech, M., González‐Camacho, F., Riksen, N. P., Aguiló, N., Yuste, J., et al. (2020) · PLoS Pathogens · doi:10.1371/journal.ppat.1008404 · Cited by 102
Effects of muramyl dipeptide treatment on resistance to infection with Toxoplasma gondii in mice
Krahenbuhl, J. L., Sharma, S., Ferraresi, R. W., & Remington, J. S. (1981) · Infection and Immunity · doi:10.1128/iai.31.2.716-722.1981 · Cited by 101
A Specific Inhibitor of PfCDPK4 Blocks Malaria Transmission: Chemical-genetic Validation
Ojo, K. K., Eastman, R. T., Vidadala, R., Zhang, Z., Rivas, K. L., Choi, R., Lutz, J. D., Reid, M. C., Fox, A. M. W., Hulverson, M. A., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit522 · Cited by 101
Hofhuis, A., van Pelt, W., van Duynhoven, Y. T. H. P., NIJHUIS, C. D. M., Mollema, L., van der Klis, F. R. M., Havelaar, A. H., & Kortbeek, L. M. (2010) · Epidemiology and Infection · doi:10.1017/s0950268810001044 · Cited by 100
Vidadala, R. S. R., Rivas, K. L., Ojo, K. K., Hulverson, M. A., Zambriski, J. A., Bruzual, I., Schultz, T. L., Huang, W., Zhang, Z., Scheele, S., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00760 · Cited by 99
Treatment of Toxoplasmosis and Neosporosis in Farm Ruminants: State of Knowledge and Future Trends
Sánchez-Sánchez, R., Vázquez, P., Ferre, I., & Ortega‐Mora, L. M. (2018) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026618666181002113617 · Cited by 99
Araujo, F. G., Shepard, R. M., & Remington, J. S. (1991) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01963942 · Cited by 98
Novel immunomodulatory drugs and neo-substrates
Gao, S., Wang, S., & Song, Y. (2020) · Biomarker Research · doi:10.1186/s40364-020-0182-y · Cited by 95 · cited 1×
“Immunomodulatory drugs comprise different classes of compounds with direct or indirect impact on the immune system (Gao et al., 2020).”
BackgroundA review on inactivation methods of Toxoplasma gondii in foods
Alizadeh, A. M., Jazaeri, S., Shemshadi, B., Hashempour‐Baltork, F., Sarlak, Z., Pilevar, Z., & Hosseini, H. (2018) · Pathogens and Global Health · doi:10.1080/20477724.2018.1514137 · Cited by 94
Young, J. C., Dominicus, C. S., Wagener, J., Butterworth, S., Ye, X., Kelly, G. P., Ordan, M., Saunders, B., Instrell, R., Howell, M. T., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-11855-w · Cited by 94
Pereboom, M., Manniën, J., Spelten, E. R., Schellevis, F., & Hutton, E. K. (2013) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-13-98 · Cited by 91
Adeyemı, O. S., Murata, Y., Sugi, T., & Kato, K. (2017) · International Journal of Nanomedicine · doi:10.2147/ijn.s122178 · Cited by 91
Teimouri, A., Azami, S. J., Keshavarz, H., Esmaeili, F., Alimi, R., Mavi, S. A., & Shojaee, S. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s158736 · Cited by 91
Overlap in the repertoires of peptides bound in vivo by a group of related class I HLA-B allotypes
Barber, L. D., Gillece-Castro, B. L., Percival, L., Li, X., Clayberger, C., & Parham, P. (1995) · Current Biology · doi:10.1016/s0960-9822(95)00039-x · Cited by 90
Lawres, L., Garg, A., Kumar, V. P., Bruzual, I., Forquer, I., Renard, I., Virji, A. Z., Boulard, P., Rodriguez, E. X., Allen, A. J., et al. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20151519 · Cited by 89
Khan, I. A., Murphy, P. M., Casciotti, L., Schwartzman, J. D., Collins, J., Gao, J.-L., & Yeaman, G. R. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.3.1930 · Cited by 88
Baumeister, S., Wiesner, J., Reichenberg, A., Hintz, M., Bietz, S., Harb, O. S., Roos, D. S., Kordes, M., Friesen, J., Matuschewski, K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019334 · Cited by 88
Phylogeography of Toxoplasma gondii points to a South American origin
Bertranpetit, E., Jombart, T., Paradis, E., et al. (2016) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2016.12.020 · Cited by 88
Behnke, M. S., Zhang, T. P., Dubey, J. P., & Sibley, L. D. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-350 · Cited by 86
Foroutan, M., Ghaffarifar, F., Sharifi, Z., & Dalimi, A. (2020) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2020.101413 · Cited by 86
Gama, L. M. D., Ribeiro-Gomes, F. L., Guimarães, U., & Arnholdt, A. C. V. (2004) · Microbes and Infection · doi:10.1016/j.micinf.2004.07.008 · Cited by 85
An enhanced GRA1–GRA7 cocktail DNA vaccine primes anti-Toxoplasma immune responses in pigs
Jongert, E., Melkebeek, V., Craeye, S. D., Dewit, J., Verhelst, D., & Cox, E. (2007) · Vaccine · doi:10.1016/j.vaccine.2007.11.058 · Cited by 84
Lifelong Persistence of Toxoplasma Cysts: A Questionable Dogma?
Rougier, S., Montoya, J. G., & Peyron, F. (2016) · Trends in Parasitology · doi:10.1016/j.pt.2016.10.007 · Cited by 84
Etewa, S. E., El-Maaty, D. A. A., Hamza, R. S., Metwaly, A. S., Sarhan, M. H., Abdelrahman, S., Fathy, G. M., & El-Shafey, M. A. (2017) · Journal of Parasitic Diseases · doi:10.1007/s12639-017-0973-8 · Cited by 84
Martynowicz, J., Augusto, L. D. S., Wek, R. C., Boehm, S. L., & Sullivan, W. J. (2019) · mBio · doi:10.1128/mbio.00381-19 · Cited by 83
Li, Z., Ramakrishnan, S., Striepen, B., & Moreno, S. N. J. (2013) · PLoS Pathogens · doi:10.1371/journal.ppat.1003665 · Cited by 82
Stanley, A. C. (2004) · Vaccine · doi:10.1016/j.vaccine.2004.04.022 · Cited by 82
Maubon, D., Bougdour, A., Wong, Y., Brenier‐Pinchart, M., Curt, A., Hakimi, M., & Pelloux, H. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00462-10 · Cited by 81
Freyre, A., Choromanski, L. J., Fishback, J. L., & Popiel, I. (1993) · Journal of Parasitology · doi:10.2307/3283610 · Cited by 80
Gollub, E. L., Leroy, V., Gilbert, R. E., Chêne, G., & Wallon, M. (2007) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2007.09.010 · Cited by 79
Khan, I. A., & Casciotti, L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.8.4503 · Cited by 77
The Induction of Acute Ileitis by a Single Microbial Antigen of Toxoplasma gondii
Rachinel, N., Buzoni–Gatel, D., Dutta, C., Mennechet, F. J. D., Luangsay, S., Minns, L. A., Grigg, M. E., Tomavo, S., Boothroyd, J. C., & Kasper, L. H. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2725 · Cited by 77
Toxoplasma gondii: The enzymic defect of a mutant resistant to 5-fluorodeoxyuridine
Pfefferkorn, E. R. (1978) · Experimental Parasitology · doi:10.1016/0014-4894(78)90077-2 · Cited by 76
Dunay, I. R., Heimesaat, M. M., Bushrab, F. N., Müller, R. H., Stocker, H., Arastéh, K., Kurowski, M., Fitzner, R., Borner, K., & Liesenfeld, O. (2004) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.48.12.4848-4854.2004 · Cited by 76
Dimier‐Poisson, I., Carpentier, R., N'Guyen, T. T. L., Dahmani, F. Z., Ducournau, C., & Betbeder, D. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2015.01.056 · Cited by 76
El-Zawawy, L. A., Said, D. E., Mossallam, S. F., Ramadan, H., & Younis, S. S. (2014) · Experimental Parasitology · doi:10.1016/j.exppara.2014.12.007 · Cited by 76
Rutaganira, F. U., Barks, J., Dhason, M. S., Wang, Q., Lopez, M. S., Long, S., Radke, J. B., Jones, N. G., Maddirala, A. R., Janetka, J. W., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01192 · Cited by 76
Garcia, J. L., Gennari, S. M., Navarro, I. T., Machado, R. Z., Sinhorini, I. L., Freire, R. L., Marana, E. R. M., Tsutsui, V. S., Contente, A. P. A., & Prudêncio, L. B. (2005) · Veterinary Parasitology · doi:10.1016/j.vetpar.2005.01.006 · Cited by 75
Bumped Kinase Inhibitor 1294 Treats Established Toxoplasma gondii Infection
Doggett, J. S., Ojo, K. K., Fan, E., Maly, D. J., & Voorhis, W. C. V. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01823-13 · Cited by 75
Boyom, F. F., Fokou, P. V. T., Tchokouaha, L. R. Y., Spangenberg, T., Mfopa, A. N., Toghueo, R. M. K., Mbouna, C. D. J., Donfack, V. F. D., & Zollo, P. H. A. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02541-14 · Cited by 74
Amiar, S., Katris, N. J., Berry, L., Dass, S., Duley, S., Arnold, C.-S., Shears, M. J., Brunet, C. D., Touquet, B., McFadden, G. I., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.02.072 · Cited by 74
Lidar, M., Langevitz, P., Barzilai, O., Ram, M., Porat‐Katz, B., Bizzaro, N., Tonutti, E., Maieron, R., Chowers, Y., Bar–Meir, S., et al. (2009) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2009.04673.x · Cited by 73
Hiszczyńska-Sawicka, E., Olędzka, G., Holec-Gąsior, L., Li, H., Xu, J. B., Sedcole, R., Kur, J., Bickerstaffe, R., & Stankiewicz, M. (2011) · Veterinary Parasitology · doi:10.1016/j.vetpar.2010.11.047 · Cited by 73
Treatment of toxoplasmic encephalitis in mice with recombinant gamma interferon
Suzuki, Y., Conley, F. K., & Remington, J. S. (1990) · Infection and Immunity · doi:10.1128/iai.58.9.3050-3055.1990 · Cited by 72
Mévélec, M.-N., Ducournau, C., Ismael, A. B., Olivier, M., Sèche, É., Lebrun, M., Bout, D. T., & Dimier‐Poisson, I. (2010) · Veterinary Research · doi:10.1051/vetres/2010021 · Cited by 71
PD-1–Mediated Attrition of Polyfunctional Memory CD8+ T Cells in Chronic Toxoplasma Infection
Bhadra, R., Gigley, J. P., & Khan, I. A. (2012) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis304 · Cited by 71
CRISPR-Cas9-based genome-wide screening of Toxoplasma gondii
Sidik, S. M., Huet, D., & Lourido, S. (2018) · Nature Protocols · doi:10.1038/nprot.2017.131 · Cited by 71
Trujillo, M., Donald, R. G. K., Roos, D. S., et al. (1996) · Biochemistry · doi:10.1021/bi952923q · Cited by 69
Guanabenz Repurposed as an Antiparasitic with Activity against Acute and Latent Toxoplasmosis
Benmerzouga, I., Checkley, L. A., Ferdig, M. T., Arrizabalaga, G., Wek, R. C., & Sullivan, W. J. (2015) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01683-15 · Cited by 68
Vaccination of pigs with the S48 strain of Toxoplasma gondii – safer meat for human consumption
Burrells, A., Benavides, J., Cantón, G., Garcia, J. L., Bartley, P. M., Nath, M., Thomson, J., Chianini, F., Innes, E. A., & Katzer, F. (2015) · Veterinary Research · doi:10.1186/s13567-015-0177-0 · Cited by 67
Ferreira, F. P., Caldart, E. T., Freire, R. L., Mitsuka‐Breganó, R., de Freitas, F. M., Miura, A. C., Mareze, M., Martins, F. D. C., Urbano, M. R., Seifert, A. L., et al. (2018) · Revista Brasileira de Parasitologia Veterinária/Brazilian Journal of Veterinary Parasitology · doi:10.1590/s1984-296120180050 · Cited by 66
CCL 2 as a potential therapeutic target for clear cell renal cell carcinoma
Arakaki, R., Yamasaki, T., Kanno, T., Shibasaki, N., Sakamoto, H., Utsunomiya, N., Sumiyoshi, T., Shibuya, S., Tsuruyama, T., Nakamura, E., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.886 · Cited by 65
Recent progress on anti-Toxoplasma drugs discovery: Design, synthesis and screening
Deng, Y. L., Wu, T., Shao‐qin, Z., & Li, C. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111711 · Cited by 64
Hopper, A. T., Brockman, A., Wise, A., Gould, J., Barks, J., Radke, J. B., Sibley, L. D., Zou, Y., & Thomas, S. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01754 · Cited by 64
Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites
Murata, Y., Sugi, T., Weiss, L. M., & Kato, K. (2017) · PLoS ONE · doi:10.1371/journal.pone.0178203 · Cited by 63
Štajner, T., Vasiljevic, Z. V., Vujić, D., Marković, M., Ristić, G., Mićić, D., Pašić, S., Ivović, V., Ajzenberg, D., & Djurković–Djaković, O. (2013) · Journal of Clinical Microbiology · doi:10.1128/jcm.01077-13 · Cited by 62
Metal nanoparticles restrict the growth of protozoan parasites
Adeyemı, O. S., Molefe, N. I., Awakan, O. J., Nwonuma, C. O., Alejolowo, O. O., Olaolu, T. D., Maimako, R. F., Suganuma, K., Han, Y., & Kato, K. (2018) · Artificial Cells Nanomedicine and Biotechnology · doi:10.1080/21691401.2018.1489267 · Cited by 61
Cong, H., Mui, E. J., Witola, W. H., Sidney, J., Alexander, J., Sette, A., Maewal, A., & McLeod, R. L. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.11.015 · Cited by 60
Immunization of Cats against Shedding of Toxoplasma Oocysts
Frenkel, J. K., & Smith, D. D. (1982) · Journal of Parasitology · doi:10.2307/3280978 · Cited by 60
Reexamining Chronic Toxoplasma gondii Infection: Surprising Activity for a “Dormant” Parasite
Sinai, A. P., Watts, E. A., Dhara, A., Murphy, R. D., Gentry, M. S., & Patwardhan, A. R. (2016) · Current Clinical Microbiology Reports · doi:10.1007/s40588-016-0045-3 · Cited by 59
Alday, P. H., Bruzual, I., Nilsen, A., Pou, S., Winter, R. W., Mamoun, C. B., Riscoe, M. K., & Doggett, J. S. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01866-16 · Cited by 59
Nanomedicine advances in toxoplasmosis: diagnostic, treatment, and vaccine applications
Assolini, J. P., Concato, V. M., Gonçalves, M. D., Carloto, A. C. M., Costa, I. C., Pavanelli, W. R., Melanda, F. N., & Costa, I. N. (2017) · Parasitology Research · doi:10.1007/s00436-017-5458-2 · Cited by 58
Optimizing Systems for Cas9 Expression in Toxoplasma gondii
Markus, B. M., Bell, G. W., Lorenzi, H., & Lourido, S. (2019) · mSphere · doi:10.1128/msphere.00386-19 · Cited by 58
Radke, J. B., Burrows, J. N., Goldberg, D. E., & Sibley, L. D. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00113 · Cited by 57
Mishima, M., Xuan, X., Yokoyama, N., Igarashi, I., Fujisaki, K., Nagasawa, H., & Mikami, T. (2002) · Parasitology Research · doi:10.1007/s004360100429 · Cited by 56
Sher, A., Tosh, K. W., & Jankovic, D. L. (2016) · Cellular and Molecular Immunology · doi:10.1038/cmi.2016.12 · Cited by 55
Luo, F., Zheng, L., Hu, Y., Liu, S., Wang, Y., Xiong, Z., Hu, X., & Tan, F. (2017) · Frontiers in Microbiology · doi:10.3389/fmicb.2017.00605 · Cited by 55
Roozbehani, M., Falak, R., Mohammadi, M., Hemphill, A., Razmjou, E., Meamar, A. R., Masoori, L., Khoshmirsafa, M., Moradi, M., & Gharavi, M. J. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.08.068 · Cited by 54 · cited 1×
“GRA4) have been encapsulated in nanoparticles and tested for immunogenicity (Roozbehani et al., 2018).”
Wang, J., Li, T., Elsheikha, H. M., Chen, K., Cong, W., Yang, W., Bai, M., Huang, S., & Zhu, X. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy211 · Cited by 54
McConnell, E. V., Bruzual, I., Pou, S., Winter, R. W., Dodean, R. A., Smilkstein, M. J., Krollenbrock, A., Nilsen, A., Zakharov, L. N., Riscoe, M. K., et al. (2018) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.8b00133 · Cited by 53
Anti-Chemokine Therapy for Inflammatory Diseases
Castellani, M. L., Bhattacharya, K., Tagen, M., Kempuraj, D., Perrella, A., Lutiis, M. A. D., Boucher, W. S., Conti, P., Theoharides, T. C., Cerulli, G. G., et al. (2007) · International Journal of Immunopathology and Pharmacology · doi:10.1177/039463200702000303 · Cited by 52
Bumped Kinase Inhibitors as therapy for apicomplexan parasitic diseases: lessons learned
Choi, R., Hulverson, M. A., Huang, W., Vidadala, R. S. R., Whitman, G. R., Barrett, L. K., Schaefer, D. A., Betzer, D. P., Riggs, M. W., Doggett, J. S., et al. (2020) · International Journal for Parasitology · doi:10.1016/j.ijpara.2020.01.006 · Cited by 52
Katzer, F., Cantón, G., Burrells, A., Palarea‐Albaladejo, J., Horton, B., Bartley, P. M., Pang, Y., Chianini, F., Innes, E. A., & Benavides, J. (2014) · Veterinary Parasitology · doi:10.1016/j.vetpar.2014.07.003 · Cited by 51
Andiappan, H., Nissapatorn, V., Sawangjaroen, N., Khaing, S. L., Salibay, C. C., Cheung, M. M. M., Dungca, J. Z., Chemoh, W., Ching, X. T., Lau, Y. L., et al. (2014) · Frontiers in Microbiology · doi:10.3389/fmicb.2014.00291 · Cited by 51
Adjuvanted multi-epitope vaccines protect HLA-A*11:01 transgenic mice against Toxoplasma gondii
Bissati, K. E., Chentoufi, A. A., Krishack, P. A., Zhou, Y., Woods, S., Dubey, J. P., Vang, L., Lykins, J. D., V, Broderick, K. E., Mui, E. J., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85955 · Cited by 51
Khan, I. A., Moretto, M. M., Wei, X., Williams, M. E., Schwartzman, J. D., & Liew, F. Y. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20011915 · Cited by 50
Anti-Toxoplasma Activity of Natural Products: A Review
Arias, J. C., Veloza, L. A., & Mantilla-Muriel, L. E. (2015) · Recent Patents on Anti-Infective Drug Discovery · doi:10.2174/1574891x10666150410120321 · Cited by 50
Research works printed but not linked: 97
- Abdelbaset, 2017, Lactate dehydrogenase in Toxoplasma gondii controls virulence, bradyzoite differentiation, and chronic infection, PLoS ONE, 12, 10.1371/journal.pone.0173745 · doi:10.1371/journal.pone.0173745
- Adeyemi, 2018, Screening of chemical compound libraries identified new anti-Toxoplasma gondii agents, Parasitol. Res., 117, 355, 10.1007/s00436-017-5698-1 · doi:10.1007/s00436-017-5698-1
- Adeyemi, 2019, Nanoparticles show potential to retard bradyzoites in vitro formation of Toxoplasma gondii, Folia Parasitol., 66, 001, 10.14411/fp.2019.001 · doi:10.14411/fp.2019.001
- Alajmi, 2019, Anti-Toxoplasma activity of silver nanoparticles green synthesizes with Phoenix dactylifera and Ziziphus spina-christi extracts which inhibits inflammation through liver regulation of cytokines in Balb/c mice, Biosci. Rep., 39, 10.1042/BSR20190379 · doi:10.1042/bsr20190379
- Aly, 2018, Advantages of bioconjugated silica-coated nanoparticles as an innovative diagnosis for human toxoplasmosis, Acta Tropica, 177, 19, 10.1016/j.actatropica.2017.09.024 · doi:10.1016/j.actatropica.2017.09.024
- Amberg-Johnson, 2019, Host cell metabolism contributes to delayed-death kinetics of apicoplast inhibitors in Toxoplasma gondii, Antimicrob. Agents Chemother., 63, 10.1128/AAC.01646-18 · DOI
- Anand, 2015, Oral administration of encapsulated bovine lactoferrin nanocapsules against intracellular parasite Toxoplasma gondii, Int. J. Nanomed., 10, 6355
- Araujo, 1997, Treatment with interleukin 12 in combination with atovaquone or clindamycin significantly increases survival of mice with acute toxoplasmosis, Antimicrob. Agents Chemother., 41, 188, 10.1128/AAC.41.1.188 · doi:10.1128/aac.41.1.188
- Araujo, 1992, In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondii, Antimicrob. Agents Chemother., 36, 326, 10.1128/AAC.36.2.326 · doi:10.1128/aac.36.2.326
- Araujo, 1974, Effect of clindamycin on acute and chronic toxoplasmosis in mice, Antimicrob. Agents Chemother., 5, 647, 10.1128/AAC.5.6.647 · doi:10.1128/aac.5.6.647
- Baatz, 2006, Reactivation of Toxoplasma retinochoroiditis under atovaquone therapy in an immunocompetent patient, Ocular Immunol. Inflamm., 14, 185, 10.1080/09273940600659740 · doi:10.1080/09273940600659740
- Balaskas, 2012, Azithromycin versus sulfadiazine and pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study, Med. Sci. Monitor, 18, CR296, 10.12659/MSM.882735 · doi:10.12659/msm.882735
- Benedetto, 1991, Effect of rIFN-gamma and IL-2 treatments in mouse and nude rat infections with Toxoplasma gondii, Eur. Cytokine Netw., 2, 107
- Bhadra, 2012, IL-7 and IL-15 do not synergize during CD8 T cell recall response against an obligate intracellular parasite, Microbes Infect., 14, 1160, 10.1016/j.micinf.2012.07.018 · doi:10.1016/j.micinf.2012.07.018
- Bosch-Driessen, 2002, A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis, American J. Ophthalmol., 134, 34, 10.1016/S0002-9394(02)01537-4 · doi:10.1016/s0002-9394(02)01537-4
- Brenier-Pinchart, 2006, The Toxoplasma surface protein SAG1 triggers efficient in vitro secretion of chemokine ligand 2 (CCL2) from human fibroblasts, Microbes Infect., 8, 254, 10.1016/j.micinf.2005.06.023 · doi:10.1016/j.micinf.2005.06.023
- Buxton, 1994, Primary and secondary responses of the ovine lymph node to Toxoplasma gondii: cell output in efferent lymph and parasite detection, J. Comp. Pathol., 111, 231, 10.1016/S0021-9975(05)80002-7 · doi:10.1016/s0021-9975(05)80002-7
- Buyukbaba Boral, 2012, Investigation of combined effectiveness of spiramycin and beta-glucan in mice models of acute toxoplasmosis and determination of IL-10, IL-12 and TNF-alpha levels, Mikrobiyoloji bulteni, 46, 446
- Camps, 2002, An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii, Mol. Microbiol., 43, 1309, 10.1046/j.1365-2958.2002.02825.x · DOI
- Carellos, 2014, Adverse socioeconomic conditions and oocyst-related factors are associated with congenital toxoplasmosis in a population-based study in Minas Gerais, Brazil, PLoS One, 9, 10.1371/journal.pone.0088588 · doi:10.1371/journal.pone.0088588
- Choromanski, 1995, Safety and efficacy of modified live feline Toxoplasma gondii vaccine, Dev. Biol. Stand., 84, 269
- da Cunha, 2012, Humoral and cellular immune responses in pigs immunized intranasally with crude rhoptry proteins of Toxoplasma gondii plus Quil-A, Vet. Parasitol., 186, 216, 10.1016/j.vetpar.2011.11.034 · doi:10.1016/j.vetpar.2011.11.034
- Delemarre, 1994, Effect of IFN-gamma on the proliferation of Toxoplasma gondii in monocytes and monocyte-derived macrophages from AIDS patients, Immunology, 83, 646
- Delemarre, 1993, Restoration of the toxoplasmastatic activity of monocytes from AIDS patients during in vivo treatment with interferon-gamma, J. Infect. Dis., 168, 516, 10.1093/infdis/168.2.516 · doi:10.1093/infdis/168.2.516
- Doggett, 2020, Orally bioavailable endochin-like quinolone carbonate ester prodrug reduces Toxoplasma gondii brain cysts, Antimicrob. Agents Chemother., 64, e00535, 10.1128/AAC.00535-20 · doi:10.1128/aac.00535-20
- Dubey, 2017, Schizogony and gametogony of oocyst-deficient T-263 strain of Toxoplasma gondii, Vet. Parasitol., 245, 160, 10.1016/j.vetpar.2017.05.024 · doi:10.1016/j.vetpar.2017.05.024
- Dubey, 1994, Persistence of immunity to toxoplasmosis in pigs vaccinated with a nonpersistent strain of Toxoplasma gondii, Am. J. Vet. Res., 55, 982, 10.2460/ajvr.1994.55.07.982 · doi:10.2460/ajvr.1994.55.07.982
- Dubey, 1998, Immunity to toxoplasmosis in pigs fed irradiated Toxoplasma gondii oocysts, J. Parasitol., 84, 749, 10.2307/3284582 · doi:10.2307/3284582
- Dumas, 1994, Evaluation of the efficacy of prolonged administration of azithromycin in a murine model of chronic toxoplasmosis, J. Antimicrob. Chemother., 34, 111, 10.1093/jac/34.1.111 · doi:10.1093/jac/34.1.111
- Ferguson, 1994, An ultrastructural study of the effect of treatment with atovaquone in brains of mice chronically infected with the ME49 strain of Toxoplasma gondii, Int. J. Exp. Pathol., 75, 111
- Frenkel, 1967, Adoptive immunity to intracellular infection, J. Immunol., 98, 1309, 10.4049/jimmunol.98.6.1309 · doi:10.4049/jimmunol.98.6.1309
- Freppel, 2019, Structure, composition, and roles of the Toxoplasma gondii oocyst and sporocyst walls, Cell Surf., 5, 10016, 10.1016/j.tcsw.2018.100016 · doi:10.1016/j.tcsw.2018.100016
- Freyre, 2007, Toxoplasma gondii: cross-immunity against the enteric cycle, Exp. Parasitol., 115, 48, 10.1016/j.exppara.2006.05.007 · doi:10.1016/j.exppara.2006.05.007
- Fu, 2011, Generation of a neutralizing human monoclonal antibody Fab fragment to surface antigen 1 of Toxoplasma gondii tachyzoites, Infect. Immun., 79, 512, 10.1128/IAI.00969-10 · doi:10.1128/iai.00969-10
- Gao, 2018, Immune response and protective effect against chronic Toxoplasma gondii infection induced by vaccination with a DNA vaccine encoding profilin, BMC Infect. Dis., 18, 117, 10.1186/s12879-018-3022-z · doi:10.1186/s12879-018-3022-z
- Gasparotto Junior, 2016, Effects of extracts from Echinacea purpurea (L) MOENCH on mice infected with different strains of Toxoplasma gondii, Parasitol. Res., 115, 3999, 10.1007/s00436-016-5167-2 · doi:10.1007/s00436-016-5167-2
- Hagras, 2019, Successful treatment of acute experimental toxoplasmosis by spiramycin-loaded chitosan nanoparticles, Exp. Parasitol., 204, 10.1016/j.exppara.2019.107717 · doi:10.1016/j.exppara.2019.107717
- Haverkos, 1987, Assessment of therapy for toxoplasma encephalitis. The TE Study Group, Am J. Med., 82, 907, 10.1016/0002-9343(87)90151-3 · doi:10.1016/0002-9343(87)90151-3
- Hegazy, 2015, Novel IMB-ELISA assay for rapid diagnosis of human toxoplasmosis using SAG-1 antigen, Jpn. J. Infect. Dis., 68, 474, 10.7883/yoken.JJID.2014.444 · doi:10.7883/yoken.jjid.2014.444
- Ivanetich, 1990, Thymidylate synthase-dihydrofolate reductase in protozoa, Exp. Parasitol., 70, 367, 10.1016/0014-4894(90)90119-W · doi:10.1016/0014-4894(90)90119-w
- Jiang, 2013, A novel immunosensor for detecting Toxoplasma gondii-specific IgM based on goldmag nanoparticles and graphene sheets, Colloids Surf., B Biointerfaces, 101, 481, 10.1016/j.colsurfb.2012.07.021 · doi:10.1016/j.colsurfb.2012.07.021
- Jiang, 2012, An agent-based model for the transmission dynamics of Toxoplasma gondii, J. Theoret. Biol., 293, 15, 10.1016/j.jtbi.2011.10.006 · doi:10.1016/j.jtbi.2011.10.006
- Kasper, 1995, IL-7 stimulates protective immunity in mice against the intracellular pathogen, Toxoplasma gondii, J. Immunol., 155, 4798, 10.4049/jimmunol.155.10.4798 · DOI
- Katlama, 1996, Atovaquone as long-term suppressive therapy for toxoplasmic encephalitis in patients with AIDS and multiple drug intolerance. Atovaquone Expanded Access Group, AIDS, 10, 1107
- Kersten, 2019, Unexpected neurologic complications following a novel lymphoma treatment 'expected' to give rise to neurologic toxicity, BMJ Case Rep., 12, 10.1136/bcr-2019-229946 · DOI
- Keyhani, 2020, Biogenic selenium nanoparticles target chronic toxoplasmosis with minimal cytotoxicity in a mouse model, J. Med. Microbiol., 69, 104, 10.1099/jmm.0.001111 · doi:10.1099/jmm.0.001111
- Kim, 2007, Bradyzoite-specific surface antigen SRS9 plays a role in maintaining Toxoplasma gondii persistence in the brain and in host control of parasite replication in the intestine, Infect. Immun., 75, 1626, 10.1128/IAI.01862-06 · doi:10.1128/iai.01862-06
- Kochanowsky, 2020, A single transcription factor drives Toxoplasma gondii differentiation, Cell, 180, 216, 10.1016/j.cell.2019.12.038 · doi:10.1016/j.cell.2019.12.038
- Konrad, 2013, Inhibitors of eIF2α dephosphorylation slow replication and stabilize latency in Toxoplasma gondii, Antimicrob. Agents Chemoth., 57, 1815, 10.1128/AAC.01899-12 · doi:10.1128/aac.01899-12
- Liang, 2020, Acquisition of exogenous fatty acids renders apicoplast-based biosynthesis dispensable in tachyzoites of Toxoplasma, J. Biol. Chem., 295, 7743, 10.1074/jbc.RA120.013004 · doi:10.1074/jbc.ra120.013004
- Lieberman, 2004, Interleukin-15-deficient mice develop protective immunity to Toxoplasma gondii, Infect. Immun., 72, 6729, 10.1128/IAI.72.11.6729-6732.2004 · doi:10.1128/iai.72.11.6729-6732.2004
- Ling, 2007, The farnesyl-diphosphate/geranylgeranyl-diphosphate synthase of Toxoplasma gondii is a bifunctional enzyme and a molecular target of bisphosphonates, J. Biol. Chem., 282, 30804, 10.1074/jbc.M703178200 · doi:10.1074/jbc.m703178200
- Ling, 2005, Bisphosphonate inhibitors of Toxoplasma gondii growth: in vitro, QSAR, and in vivo investigations, J. Med. Chem., 48, 3130, 10.1021/jm040132t · DOI
- Long, 2016, Analysis of noncanonical calcium-dependent protein kinases in Toxoplasma gondii by targeted gene deletion using CRISPR/Cas9, Infect. Immun., 84, 1262, 10.1128/IAI.01173-15 · doi:10.1128/iai.01173-15
- Machala, 2015, Toxoplasmosis in immunocompromised patients, Epidemiol. Mikrobiol. Imunol., 64, 59
- Mareze, 2019, Socioeconomic vulnerability associated to Toxoplasma gondii exposure in southern Brazil, PLoS One, 14, 10.1371/journal.pone.0212375 · DOI
- Martin, 2001, Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy, J. Med. Chem., 44, 909, 10.1021/jm0002578 · doi:10.1021/jm0002578
- Martorelli Di Genova, 2019, Intestinal-delta-6-desaturase activity determines hots range for Toxoplasma sexual reproduction, PLoS Biol., 17, 10.1371/journal.pbio.3000364 · doi:10.1371/journal.pbio.3000364
- Martynowicz, 2020, Efficacy of guanabenz combination therapy against chronic toxoplasmosis across multiple mouse strains, Antimicrob. Agents Chemother., 10.1128/AAC.00539-20 · doi:10.1128/aac.00539-20
- Mateus-Pinilla, 2002, A computer simulation of the prevention of the transmission of Toxoplasma gondii on swine farms using a feline T. gondii vaccine, Prev. Vet. Med., 55, 17, 10.1016/S0167-5877(02)00057-0 · doi:10.1016/s0167-5877(02)00057-0
- McLeod, 2006, Severe sulfadiazine hypersensitivity in a child with reactivated congenital toxoplasmic chorioretinitis, Pediatr. Infect. Dis. J., 25, 270, 10.1097/01.inf.0000202070.59190.9a · doi:10.1097/01.inf.0000202070.59190.9a
- McLeod, 2014, Management of congenital toxoplasmosis, Curr. Pediatr. Rep., 2, 166, 10.1007/s40124-014-0055-7 · doi:10.1007/s40124-014-0055-7
- Medawar-Aguilar, 2019, Serological diagnosis of toxoplasmosis disease using a fluorescent immunosensor with chitosan-ZnO-nanoparticles, Anal. Biochem., 564–565, 116, 10.1016/j.ab.2018.10.025 · doi:10.1016/j.ab.2018.10.025
- Megged, 2008, Breakthrough cerebral toxoplasmosis in a patient receiving atovaquone prophylaxis after a hematopoietic stem cell transplantation, Pediatr. Transplant., 12, 902, 10.1111/j.1399-3046.2007.00891.x · doi:10.1111/j.1399-3046.2007.00891.x
- Mui, 2005, Triazine Inhibits Toxoplasma gondii tachyzoites in vitro and in vivo, Antimicrob. Agents Chemother., 49, 3463, 10.1128/AAC.49.8.3463-3467.2005 · doi:10.1128/aac.49.8.3463-3467.2005
- Mui, 2008, Novel triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo, PLoS Neglect. Trop. Dis., 2, 10.1371/journal.pntd.0000190 · doi:10.1371/journal.pntd.0000190
- Narasimhan, 2008, Translation regulation by eukaryotic initiation factor-2 kinases in the development of latent cysts in Toxoplasma gondii, J. Biol. Chem., 283, 16591, 10.1074/jbc.M800681200 · DOI
- Nishimura, 2017, CCR5 Is involved in interruption of pregnancy in mice infected with Toxoplasma gondii during early pregnancy, Infect. Immun., 85, e00257, 10.1128/IAI.00257-17 · doi:10.1128/iai.00257-17
- Nogareda, 2014, Incidence and prevalence of Toxoplasma gondii infection in France, 1980–2020: model-based estimation, Epidemiol. Infect., 142, 1661, 10.1017/S0950268813002756 · doi:10.1017/s0950268813002756
- O'Connell, 1988, Toxoplasmosis in sheep. II. The ability of a live vaccine to prevent lamb losses after an intravenous challenge with Toxoplasma gondii, NZ Vet. J., 36, 1, 10.1080/00480169.1988.35461 · doi:10.1080/00480169.1988.35461
- Omata, 1996, Toxoplasma gondii: experimental infection in cats vaccinated with 60Co-irradiated tachyzoites, Vet. Parasitol., 65, 173, 10.1016/S0304-4017(96)00973-9 · doi:10.1016/s0304-4017(96)00973-9
- Pearson, 1999, Atovaquone for the treatment of Toxoplasma retinochoroiditis in immunocompetent patients, Ophthalmology, 106, 148, 10.1016/S0161-6420(99)90021-0 · DOI
- Pfefferkorn, 1993, Mutants of Toxoplasma gondii resistant to atovaquone (566C80) or decoquinate, J. Parasitol., 79, 559, 10.2307/3283383 · doi:10.2307/3283383
- Pfefferkorn, 1983, Toxoplasma gondii: genetic crosses reveal phenotypic suppression of hydroxyurea resistance by fluorodeoxyuridine resistance, Exp. Parasitol., 55, 207, 10.1016/0014-4894(83)90015-2 · doi:10.1016/0014-4894(83)90015-2
- Pfefferkorn, 1992, Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant, Antimicrob. Agents Chemother., 36, 1091, 10.1128/AAC.36.5.1091 · doi:10.1128/aac.36.5.1091
- Pott, 2013, Isolated cerebellar toxoplasmosis as a complication of HIV infection, Int. J. STD AIDS, 24, 70, 10.1258/ijsa.2012.012189 · doi:10.1258/ijsa.2012.012189
- Romand, 1993, In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii, Antimicrob. Agents Chemother., 37, 2371, 10.1128/AAC.37.11.2371 · doi:10.1128/aac.37.11.2371
- Rothova, 1998, Azithromycin for ocular toxoplasmosis, Br. J. Ophthalmol., 82, 1306, 10.1136/bjo.82.11.1306 · doi:10.1136/bjo.82.11.1306
- Serranti, 2011, Congenital toxoplasmosis treatment, Eur. Rev. Med. Pharmacol. Sci., 15, 193
- Shakibaie, 2020, Prophylactic effects of biogenic selenium nanoparticles on acute toxoplasmosis: an in vivo study, Ann. Med. Surg., 54, 85, 10.1016/j.amsu.2020.04.010 · doi:10.1016/j.amsu.2020.04.010
- Sharif, 2016, The efficacy of herbal medicines against Toxoplasma gondii during the last 3 decades: a systematic review, Can. J. Physiol. Pharmacol., 94, 1237, 10.1139/cjpp-2016-0039 · doi:10.1139/cjpp-2016-0039
- Shubar, 2008, A new combined flow-cytometry-based assay reveals excellent activity against Toxoplasma gondii and low toxicity of new bisphosphonates in vitro and in vivo, J. Antimicrob. Chemother., 61, 1110, 10.1093/jac/dkn047 · doi:10.1093/jac/dkn047
- Singh, 2014, Serologic prevalence of Toxoplasma gondii in Indian women of child bearing age and effects of social and environmental factors, PLoS Negl. Trop. Dis., 8, 10.1371/journal.pntd.0002737 · doi:10.1371/journal.pntd.0002737
- Sullivan, 2004, Parasite-specific eIF2 (eukaryotic initiation factor-2) kinase required for stress-induced translation control, Biochem. J., 380, 523, 10.1042/bj20040262 · DOI
- Suzuki, 1990, The effect of anti-IFN-gamma antibody on the protective effect of Lyt-2+ immune T cells against toxoplasmosis in mice, J. Immunol., 144, 1954, 10.4049/jimmunol.144.5.1954 · doi:10.4049/jimmunol.144.5.1954
- Tu, 2020, MAG2, a Toxoplasma gondii bradyzoite stage-specific cyst matrix protein, mSphere, 5, e00100, 10.1128/mSphere.00100-20 · doi:10.1128/msphere.00100-20
- Turner, 2013, Modeling effective transmission pathways and control of the worlds’ most successful parasite, Theor. Pop. Biol., 86, 50, 10.1016/j.tpb.2013.04.001 · doi:10.1016/j.tpb.2013.04.001
- Velázquez-Hernández, 2019, Knolwedge and practices regarding toxoplasmosis in housewives: a cross sectional study in a northern Mexican city, PLoS One, 14, 10.1371/journal.pone.0222094 · doi:10.1371/journal.pone.0222094
- Villegas, 2002, Susceptibility of interleukin-2-deficient mice to Toxoplasma gondii is associated with a defect in the production of gamma interferon, Infect. Immun., 70, 4757, 10.1128/IAI.70.9.4757-4761.2002 · DOI
- Waldeland, 1983, Temperature-sensitive mutants of Toxoplasma gondii: pathogenicity and persistence in mice, J. Parasitol., 69, 171, 10.2307/3281293 · doi:10.2307/3281293
- Walker, 2013, Sex and Eimeria: a molecular perspective, Parasitology, 140, 1701, 10.1017/S0031182013000838 · doi:10.1017/s0031182013000838
- Welsch, 2016, Discovery of potent and selective lLeads against Toxoplasma gondii dihydrofolate reductase via structure-based design, ACS Med. Chem. Lett., 7, 1124, 10.1021/acsmedchemlett.6b00328 · doi:10.1021/acsmedchemlett.6b00328
- Xu, 2013, DNA detection of Toxoplasma gondii with a magnetic molecular beacon probe via CdTe@Ni quantum dots as energy donor, J. Nanomater., 2013, 62, 10.1155/2013/473703 · doi:10.1155/2013/473703
- Yang, 2009, A quick and parallel analytical method based on quantum dots labeling for TORCH-related antibodies, Nanoscale Res. Lett., 4, 1469, 10.1007/s11671-009-9422-7 · doi:10.1007/s11671-009-9422-7
- Yardley, 2002, In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii, Antimicrob. Agents Chemother., 46, 929, 10.1128/AAC.46.3.929-931.2002 · doi:10.1128/aac.46.3.929-931.2002
- Zhang, 2014, Potent and selective inhibitors of CDPK1 from T. gondii and C. parvum based on a 5-aminopyrazole-4-carboxamide scaffold, ACS Med. Chem. Lett., 5, 40, 10.1021/ml400315s · doi:10.1021/ml400315s
- Zulpo, 2012, Oocyst shedding in cats vaccinated by the nasal and rectal routes with crude rhoptry proteins of Toxoplasma gondii, Exp. Parasitol., 131, 223, 10.1016/j.exppara.2012.04.006 · doi:10.1016/j.exppara.2012.04.006
Cited by
Li, D., Zhang, Y., Li, S., & Zheng, B. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2023.1145114 · Cited by 22
Current control options and a way towards risk-based control of Toxoplasma gondii in the meat chain
Kuruca, L., Belluco, S., Vieira-Pinto, M., Antic, D., & Blagojevic, B. (2023) · Food Control · doi:10.1016/j.foodcont.2022.109556 · Cited by 21
Metadata
- Authors
- Smith, N. C., Goulart, C., Hayward, J. A., Kupz, A., Miller, C. M., & van Dooren, G. G.
- Venue
- International Journal for Parasitology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 51
- Issue
- 2-3
- Pages
- 95-121
- ISSN
- 0020-7519 (ISSN-L)
- OpenAlex
- W3117286581
- Cited by
- 286
- References
- 280
- FWCI
- 21.37
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by/4.0/ (vor)
- Funders
- National Health and Medical Research Council
- Australian Research Council
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.